Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Editas Medicine (EDIT) has 5 years of Long-Term Investments data on file, last reported at $39.2 million in Q2 2024.

• Long-Term Investments for Q2 2024 came in at $39.2 million, down 18.45% year-over-year; the trailing twelve-month figure through Jun 2024 was $39.2 million (down 18.45% YoY), and the FY2023 annual result was $104.0 million, up 11.74% from the prior year.
• Long-Term Investments eased to $39.2 million in Q2 2024 per EDIT's latest filing, from $80.6 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $120.1 million in Q4 2021 and troughed at $39.2 million in Q2 2024.
• A 5-year average of $82.3 million and a median of $85.4 million in 2021 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments jumped 115.65% in 2021, then tumbled 40.68% in 2022.
• A 5-year view of Long-Term Investments shows it stood at $109.7 million in 2020, then gained by 9.49% to $120.1 million in 2021, then dropped by 22.47% to $93.1 million in 2022, then rose by 11.74% to $104.0 million in 2023, then tumbled by 62.32% to $39.2 million in 2024.
• Business Quant data shows EDIT's Long-Term Investments at $39.2 million in Q2 2024, $80.6 million in Q1 2024, and $104.0 million in Q4 2023.